Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis |
| |
Authors: | Jing Hu Liyun Chen |
| |
Institution: | 1. Deptarment of Pharmacy, Shanghai Ruijin Rehabilitation Hospital, Shanghai 200023, China;2. Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine, China |
| |
Abstract: | AimThe effects of dipeptidyl peptide-4 inhibitors (DPP-4is) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) on type 2 diabetes mellitus (T2DM) on cardiovascular events and all-cause mortality were compared.MethodsThe literature on DPP-4is and SGLT-2is treatment of T2DM was searched through Pubmed, Embase, and the web of science databases with the search deadline May 15, 2020. Network meta-analysis (NMA) was used to compare the effects of two types of inhibitors on cardiovascular events (major adverse cardiovascular events (MACE), nonfatal myocardial infarction (MI), nonfatal stroke, and cardiovascular (CV) death) and all-cause mortality in T2DM patients.ResultsA total of 15 articles were screened, including 125,796 patients. Compared with DPP-4is, SGLT-2is can significantly reduce MACE OR: 0.86 95% CI (0.78, 0.92)], CV death OR: 0.85 95% CI (0.71, 1.01)], nonfatal MI OR: 0.84 95%CI (0.74, 0.95)] and all-cause mortality OR: 0.78 95% CI (0.69, 0.89)]. For nonfatal stroke, DPP-4is and SGLT-2is have no statistically significant difference OR: 0.99 95% CI (0.91, 1.07)].ConclusionThese data indicate that SGLT-2is is more beneficial to MACE and all-cause mortality in T2DM patients than DPP-4is. |
| |
Keywords: | Type 2 diabetes mellitus Dipeptidyl peptide-4 inhibitors Sodium-glucose cotransporter-2 inhibitors Major adverse cardiovascular events All-cause mortality |
本文献已被 ScienceDirect 等数据库收录! |
|